Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
0.6500
-0.0450 (-6.47%)
At close: Mar 28, 2025, 4:00 PM
0.6200
-0.0300 (-4.62%)
After-hours: Mar 28, 2025, 7:53 PM EST

Calidi Biotherapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
Sep '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
--0.050.45-
Revenue Growth (YoY)
---89.98%--
Cost of Revenue
--0.010.09-
Gross Profit
--0.030.36-
Selling, General & Admin
16.5515.9815.96.163.59
Research & Development
11.0213.017.263.83.18
Operating Expenses
27.5728.9923.169.966.77
Operating Income
-27.57-28.99-23.13-9.61-6.77
Interest Expense
-0.98-1.07-0.16-0.61-0.16
Other Non Operating Income (Expenses)
2.271.33-2.130.24-1.05
EBT Excluding Unusual Items
-26.28-28.73-25.42-9.98-7.99
Other Unusual Items
--0.47--0.060.06
Pretax Income
-26.28-29.2-25.42-10.92-7.93
Income Tax Expense
0.010.020.010.010
Net Income
-26.28-29.22-25.43-10.93-7.94
Net Income to Common
-27.95-29.22-25.43-10.93-7.94
Shares Outstanding (Basic)
52122
Shares Outstanding (Diluted)
52122
Shares Change (YoY)
402.94%98.55%-56.93%15.26%-
EPS (Basic)
-5.51-17.30-29.90-5.54-4.63
EPS (Diluted)
-5.51-17.30-29.90-5.54-4.63
Free Cash Flow
-19.54-27.57-13.64-7.98-5.18
Free Cash Flow Per Share
-3.85-16.32-16.04-4.04-3.02
Gross Margin
--68.89%79.06%-
Operating Margin
---51395.56%-2139.42%-
Profit Margin
---56504.44%-2434.97%-
Free Cash Flow Margin
---30315.56%-1777.28%-
EBITDA
-27.17-28.6-22.87-9.45-6.67
D&A For EBITDA
0.40.390.260.160.11
EBIT
-27.57-28.99-23.13-9.61-6.77
Revenue as Reported
--0.05--
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q